HC Wainwright & Co. initiates coverage of Monte Rosa Therapeutics with Buy rating, $25 price target

Marti Technologies (MRT) reported Q2 2026 revenue of $20M, beating estimates and up 141% YoY. Despite a wider-than-expected adjusted loss of $0.15 per share, the company achieved positive adjusted EBITDA of $2.9M and raised its full-year outlook to $85M in revenue and $7M in adjusted EBITDA. Shares rose 5% in pre-market trading.

Marti Technologies, Inc. (MRT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Marti Achieves Record Second Quarter with 141% Revenue Growth, 77% Gross Profit Margin, Significant Improvement in Profitability, and Increased Guidance Ride-hailing growth, platform monetization, and expanding margins drove record profitability and support increased

Marti Technologies (NYSE American: MRT) said it launched its ride-hailing service in 10 additional Turkish cities, expanding coverage to 30 cities and about 85% of Türkiye’s GDP. The company reported rider and driver shares outside Istanbul rose to 45% and 36% as of Aug. 11, 2026. Marti reiterated FY2026 guidance of $85M revenue and $7M Adjusted EBITDA, expecting accretion starting 2027.

Marti Technologies (NYSE American: MRT) raised its fiscal 2026 guidance, citing stronger-than-expected performance. The company now expects revenue of $85 million and adjusted EBITDA of $7 million, up from $70 million and $1 million previously. Management attributes the change to larger addressable markets, faster rider and driver adoption, and higher gross margins. It plans to report Q2 2026 results in August 2026.

Oppenheimer reiterated an Outperform rating and $54 price target for Capricor Therapeutics (CAPR) after a webinar on FDA data, citing robust HOPE-3 trial results. The stock is down 74% in six months. Other analysts also upgraded CAPR, with targets up to $25, anticipating regulatory milestones.

Goldman Sachs reduced its price target for Corteva (CTVA) to $20 from $96, maintaining a Buy rating. The company spun off its seed business, Vylor, on October 1, 2026. Corteva shares are at $14.45, up 15% in a week. Goldman values Corteva at 10.5x EV/EBITDA, projecting $600M annual free cash flow in 2027-29. Other analysts have also adjusted targets post-spinoff.